RCKT ROCKET PHARMACEUTICALS INC US FDA Inspections 8-K Filing 2024 - FDA Review Period Extended Rocket Pharmaceuticals, Inc. announced that the FDA has extended the Priority Review period for the Biologics License Application for KRESLADI for severe Leukocyte Adhesion Deficiency-I by three months.Get access to all SEC 8-K filings of the ROCKET PHARMACEUTICALS INC